Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial

Aldeyra Therapeutics, Inc. ALDX (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has enrolled the first patient in its Phase II clinical trial of NS2 for the treatment of noninfectious anterior uveitis. The study is being conducted at top U.S. anterior uveitis clinical trial sites, and led by Dr. Stephen Foster, a recognized clinical expert in ocular inflammation. Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "We continue to make progress in the clinical development of NS2, most recently with the dosing of the first patient in our Phase II clinical trial for noninfectious anterior uveitis. This is another significant step for Aldeyra as we work to demonstrate the therapeutic potential of NS2 in the treatment of inflammatory diseases. We look forward to providing data from this trial, as well as our recently initiated Phase II clinical trial for Sjögren-Larsson Syndrome, by the end of 2015." A synopsis of the trial is available on www.clinicaltrials.gov.